Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language

This article was originally published in The Pink Sheet Daily

Executive Summary

April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.

You may also be interested in...

BIO Establishes Principles For Follow-on Biologics To Guide Lawmakers

In letters sent to legislators, BIO asks Congress to adopt the principles, emphasizing patient health and biotech innovation.

Drug Safety Bill From Sens. Kennedy And Enzi Faces Rival Version In The House

Reps. Waxman and Markey introduce legislation to give FDA stronger post-market enforcement authority, including higher fines than in a Senate version of the bill.

Generic Biologic Bill Needs Clinical Data Requirements, Sen. Hatch Says

At Senate hearing, co-author of ANDA legislation says that FDA should require clinical trials from sponsors seeking follow-on biologic approval.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts